Neurelis, Inc., a specialty pharmaceutical company focused on the treatment of central nervous system disorders, today announced that it has finalized a Series A financing round. The investment, led by LYZZ Capital, is intended to advance the company’s lead program, NRL-1 (intranasal diazepam), through the remaining clinical work in preparation for FDA submission of a […]
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.